Pacira BioSciences, Inc. (PCRX)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 778,348 | 870,130 | 775,010 | 730,408 | 619,688 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $778,348K
= 0.00
Based on the provided data, Pacira BioSciences, Inc. has consistently maintained a debt-to-equity ratio of 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt financing relative to its equity during this period. A debt-to-equity ratio of 0.00 suggests that the company has a conservative capital structure with little to no financial leverage, which may imply lower financial risk and potentially greater stability. However, it is important to note that a very low or zero debt-to-equity ratio may also signify missed opportunities for growth and possibly underutilization of leverage for strategic investments or expansion.
Peer comparison
Dec 31, 2024